Adamant Biomedical Investments AG

Q3 2014 13F Holdings Report, Stock Holdings

Signature - Title: Dr. Cyrill Zimmerman - CEO
Location: Zurich, Switzerland
Holdings as of: 30 Sep 2014
Value $: $391M
Num holdings: 96
Filing time: 14 Nov 2014, 15:18:24 UTC
Form type: 13F-HR
Description: All US holdings of this investor are reported in this report. Top holdings included GILD, CELG, BIIB, AMGN, and B108PS.
Next filing: Q4 2014 - 13 Feb 2015
SEC: View on sec.gov

Sym	Weight	Trade Impact	Company	Class	Shares Change	Activity	Value Change $	Value $	* Price $	Shares	Principal

Compare Q3 2014 to

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.

Person Signing this Report on Behalf of Reporting Manager:

Name	Title	City, State	Date
Dr. Cyrill Zimmerman	CEO	Zurich, Switzerland	14 Nov 2014